Home Stock

Stock Research: Pacira BioSciences

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Pacira BioSciences

NSQ:PCRX US6951271005
100
  • Value
    84
  • Growth
    45
  • Safety
    Safety
    87
  • Combined
    88
  • Sentiment
    87
  • 360° View
    360° View
    100
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Pacira BioSciences is a pharmaceutical company specializing in non-opioid treatments for pain management. The company operates in the pharmaceutical industry, with key products including EXPAREL, ZILRETTA, and iovera. Pacira BioSciences operates in the US. In the last fiscal year, the company had 790 employees, a market cap of $1,060 million, profits of $531 million, and revenue of $701 million.

more

ANALYSIS: With an Obermatt 360° View of 100 (better than 100% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Pacira BioSciences are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Pacira BioSciences. The consolidated Value Rank has an attractive rank of 84, which means that the share price of Pacira BioSciences is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 84% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 87. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 87. But the consolidated Growth Rank has a low rank of 45, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 55 of its competitors have better growth. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank 360° View
Country USA
Industry Pharmaceuticals
Size Medium
Website pacira.com
Index
NASDAQ
Pacira BioSciences stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 20-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 74 49 29
Growth
45 67 79 65
Safety
Safety
87 79 58 61
Sentiment
87 44 75 30
360° View
360° View
100 91 91 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
13 11 64 43
Opinions Change
50 82 50 11
Pro Holdings
n/a 82 63 61
Market Pulse
79 19 63 70
Sentiment
87 44 75 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 74 49 29
Growth
45 67 79 65
Safety Safety
87 79 58 61
Combined
88 100 81 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
94 57 46 30
Price vs. Earnings (P/E)
32 90 75 63
Price vs. Book (P/B)
69 61 50 38
Dividend Yield
1 1 1 1
Value
84 74 49 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
51 54 64 69
Profit Growth
75 43 60 71
Capital Growth
48 94 78 31
Stock Returns
20 39 47 55
Growth
45 67 79 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
32 49 36 42
Refinancing
98 67 59 51
Liquidity
69 66 64 65
Safety Safety
87 79 58 61

Similar Stocks

Discover high‑ranked alternatives to Pacira BioSciences and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Labcorp

NYQ:LH
Country: USA
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

D.R. Horton

NYQ:DHI
Country: USA
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The stock offers good value, safe financing, and positive sentiment. However, it has below-average growth expectations. It is well-suited for conservative buy-and-hold investors who prioritize stability and low valuation over growth.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews